The latest update is out from XR Immersive Tech Inc. ( (TSE:VRAI) ).
XR Immersive Tech Inc. has acquired Continuous Glucose Monitoring (CGM) technology from InsulinQ, marking a strategic expansion into the healthcare market. This acquisition allows the company to offer a more affordable and accessible CGM solution, aiming to disrupt the diabetes market dominated by expensive devices from companies like Dexcom and Abbott. By integrating InsulinQ’s cutting-edge technology, XR Immersive Tech seeks to provide real-time, user-friendly glucose monitoring, enhancing diabetes management and overall health optimization. This move is part of the company’s broader vision to merge technology and healthcare, potentially impacting the $4.9 trillion U.S. healthcare sector and delivering significant shareholder value.
More about XR Immersive Tech Inc.
XR Immersive Tech Inc. operates in the immersive technology industry and is expanding into the healthcare sector. The company focuses on developing innovative, user-friendly solutions leveraging AI, data analytics, and user-centric design to address major challenges in healthcare and entertainment.
YTD Price Performance: 29.41%
Average Trading Volume: 11,536
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$4.15M
For a thorough assessment of VRAI stock, go to TipRanks’ Stock Analysis page.